MedWatch·Financial report·Business & finance·4mo agoJyske Bank sees strong prospects for Amplifon after its purchase of GN Hearing and share price dropJyske Bank analyst Janne Vincent Kjær expresses a positive outlook on Amplifon following its acquisition of GN Hearing, noting that uncertainty around a major capital increase is diminishing alongside a share price decline.＋Save
MedWatch·Industry news·Hearing aids·4mo agoWSA adds AI to hearing aids and hopes for a turning point in wholesaleWSA is betting on optional AI features and frequent software updates for the Widex brand to regain competitive ground in the wholesale hearing aid market, where rivals are currently outpacing its growth.＋Save
MedWatch·Industry news·AI & technology·4mo agoWSA's selective AI to stem "waterfall" of hearing aid disuseWSA's CEO argues that AI in hearing aids should be selectively applied to specific acoustic environments rather than treated as a universal solution, challenging the industry's current narrative.＋Save
MedWatch·Financial report·Business & finance·4mo agoSalary package for Sonova CEO is USD 1.6 million below his predecessor'sSonova CEO Eric Bernard's total compensation package is USD 1.6 million below his predecessor's, though it remains competitive with peer executives at rival hearing-health companies.＋Save
MedWatch·Financial report·Business & finance·4mo agoSonova beats earnings guidance and forecasts growth for 2026/27Sonova exceeded earnings guidance and projects 5–8% sales growth for fiscal year 2026/27 (April–March), according to a report by MedWatch.＋Save
MedWatch·Industry news·Business & finance·4mo agoWS Audiology moves closer to IPO as debt and interest costs fallWS Audiology is moving closer to an IPO as the company reduces its debt load and gearing ratio, long cited as a key prerequisite for a public listing.＋Save
MedWatch·Industry news·Business & finance·4mo agoWS Audiology puts faith in own brands despite Italian-Danish megadealWS Audiology is doubling down on its own brands and innovation strategy while monitoring the potential acquisition of GN's hearing aid business by Amplifon.＋Save
MedWatch·Industry news·Business & finance·4mo agoWS Audiology lags behind in key business area and goes all in on next wave of productsWS Audiology is underperforming in a key business segment and is banking on upcoming product launches, though meaningful financial impact is not expected until the next fiscal year.＋Save
MedWatch·Financial report·Business & finance·4mo agoWS Audiology maintains guidance after positive Q2 growthWS Audiology maintained its full-year guidance following positive Q2 growth, though weak wholesale business performance—attributed to the timing of product launches—tempered overall results.＋Save
MedWatch·Industry news·Business & finance·4mo agoGN partner move could reshape US hearing aid market: “A real game-changer"GN, both a supplier to and shareholder in NationsBenefits, may reshape the US discount hearing aid market as NationsBenefits is set to take over several hundred hearing centers.＋Save
MedWatch·Industry news·Business & finance·5mo agoItalian owners evoke "mixed feelings" at GNGN's planned sale of its hearing aid unit to Italian retailer Amplifon is generating mixed staff sentiment, with management pledging investment in Denmark but questions remaining over the facility's identity.＋Save
MedWatch·Industry news·Business & finance·5mo agoGN launches cost-cutting program: Aims to save USD 31.5 million per yearGN has announced a cost-cutting program targeting annual savings of USD 31.5 million, with the stated goal of improving the company's future earnings performance.＋Save
MedWatch·Financial report·Business & finance·5mo agoDanske Bank sees promising outlook for Demant after strong Q1Danske Bank issued a positive outlook on Demant following strong Q1 results, highlighting the relaunch of the Oticon Zeal hearing aid as a notable development.＋Save
MedWatch·Financial report·Business & finance·5mo agoDemant delivers strong start to the year on relaunch momentumDemant reports a strong start to fiscal 2026, driven by relaunch momentum, and maintains its full-year financial outlook.＋Save
MedWatch·Industry news·Business & finance·5mo agoJyske Bank: Demant’s strong start points to high-end resultsJyske Bank analyst Janne Vincent Kjær says Demant is on track to meet 2026 expectations following a strong start to the fiscal year.＋Save
MedWatch·Industry news·Business & finance·5mo agoDemant CEO teases new launches: "Our platform is very strong"Demant's CEO hints at upcoming product launches, crediting the Oticon Zeal's strong performance for lifting the broader portfolio in Q1 2026.＋Save
MedWatch·Financial report·Business & finance·5mo agoAmplifon upgrades earnings guidance despite flat revenue – ready for GN mega-mergerAmplifon upgrades its full-year 2026 earnings guidance, projecting 3% organic growth and improved margins, while managing the ongoing integration of GN Hearing.＋Save
MedWatch·Financial report·Business & finance·5mo agoDemant maintains guidance, sees lower-end outcome as "less likely"Demant maintains its organic growth guidance of 3–6% while characterizing a lower-end outcome as less likely, according to a financial update reported by MedWatch.＋Save
MedWatch·Financial report·Business & finance·5mo agoDanske Bank sees potential focus on Demant’s miniature product launch and GN’s sale to Amplifon in interim reportDanske Bank analysts assessed Demant's need for new product launches to sustain sales growth and flagged GN's potential sale to Amplifon as key topics ahead of the companies' interim reports.＋Save
MedWatch·Industry news·Hearing aids·5mo agoDemant launches Oticon Zeal through retail channels in the USDemant has launched the Oticon Zeal hearing aid through US retail channels, including inclusion in the Department of Veterans Affairs hearing aid contract.＋Save
MedWatch·Industry news·Business & finance·5mo agoEQT has selected banks for a potential IPO of WS AudiologyPrivate equity firm EQT has selected banks for a potential IPO of WS Audiology, though sources indicate no final decision has been made.＋Save
